2014 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
10/01/14AuraSense Therapeutics Expands Leadership Team
Gordon Beck Named Vice President of Business Development and Helen Kim Joins Board of Directors SKOKIE, Ill., Oct 01, 2014 (GLOBE NEWSWIRE via COMTEX) -- AuraSense Therapeutics, the pioneer in developing Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, today announced that Gordon Beck, Ph.D. has joined AuraSense Therapeutics' executive leadership team as vice president of business development. The Company also added Helen S. Kim, MBA to its Board... 
Printer Friendly Version
07/23/14AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer
SKOKIE, Ill., July 23, 2014 /PRNewswire/ -- AuraSense Therapeutics, the pioneer in developing spherical nucleic acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, announced today that David Snyder has joined AuraSense Therapeutics' executive leadership team as chief financial officer effective July 11.Prior to joining AuraSense Therapeutics, Mr. Snyder was Executive Vice President and Chief Financial Officer of Cellular Dynamics International Inc., where he wa... 
Printer Friendly Version
06/17/14AuraSense Therapeutics Completes $13.6 Million Series C Equity Investment
SKOKIE, Ill., June 17, 2014 /PRNewswire/ -- AuraSense Therapeutics, a Chicago-based biopharmaceutical company commercializing spherical nucleic acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, has announced the close of its Series C financing that included an investment by Bill Gates.  "Based on the success AuraSense Therapeutics has had in its extensive animal trials, we have ambitious plans to rapidly advance SNA™ constructs into the clinic," said Dr. David Gil... 
Printer Friendly Version

Print Page  | E-mail Page  | RSS Feeds  | E-mail Alerts  | IR Contacts  | Financial Tear Sheet